A Review of the Use of Secukinumab for Psoriatic Arthritis.

about

The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis

P2860

Q58761666-99967DED-C235-4F74-A64A-00A1773CA783

P2860

A Review of the Use of Secukinumab for Psoriatic Arthritis.

Item

http://www.wikidata.org/entity/Q47160133

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@en

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@nl

type

Item

label

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@en

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@nl

prefLabel

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@en

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@nl

P1476

A Review of the Use of Secukinumab for Psoriatic Arthritis.

@en

P2093

Emily Rose Shealy

http://www.w3.org/2001/XMLSchema#string

Margaret Wetzel

http://www.w3.org/2001/XMLSchema#string

Nora C Vera

http://www.w3.org/2001/XMLSchema#string

Steven R Feldman

http://www.w3.org/2001/XMLSchema#string

P2860

Secukinumab for rheumatology: development and its potential place in therapy

Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Interleukin-17 and type 17 helper T cells

Update on biologic safety for patients with psoriasis during pregnancy.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

IL-17 signaling in host defense against Candida albicans.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

P2888

s40744-017-0076-0

P304

233-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-017-0076-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nupur U Patel

P577

2017-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28849401

http://www.w3.org/2001/XMLSchema#string

P932

5696288

http://www.w3.org/2001/XMLSchema#string

A Review of the Use of Secukinumab for Psoriatic Arthritis.

about

P2860

P2860

A Review of the Use of Secukinumab for Psoriatic Arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932